Key result
Idiopathic inflammatory myopathies linked to a 3-point higher median fatigue score versus healthy controls.
Why the study?
Idiopathic inflammatory myopathies confer a significant risk of disability and poor quality of life, but fatigue remains under-reported in these individuals.
Cross-Sectional (n=6,988)
Yes
Absolute Event Rate: 5% vs 2%
p-value: p=<0.001
Patients with idiopathic inflammatory myopathies experience considerable fatigue, comparable to other systemic autoimmune diseases and significantly higher than healthy individuals, with women and Caucasians reporting greater fatigue.
Idiopathic inflammatory myopathies (IIMs) confer a significant risk of disability and poor quality of life, though fatigue, an important contributing factor, remains under-reported in these individuals. We aimed to compare and analyze differences in visual analog scale (VAS) scores (0-10 cm) for fatigue (VAS-F) in patients with IIMs, non-IIM systemic autoimmune diseases (SAIDs), and healthy controls (HCs). We performed a cross-sectional analysis of the data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) international patient self-reported e-survey. The COVAD survey was circulated from December 2020 to August 2021, and details including demographics, COVID-19 history, vaccination details, SAID details, global health, and functional status were collected from adult patients having received at least one COVID-19 vaccine dose. Fatigue experienced 1 week prior to survey completion was assessed using a single-item 10 cm VAS. Determinants of fatigue were analyzed in regression models. Six thousand nine hundred and eighty-eight respondents (mean age 43.8 years, 72% female; 55% White) were included in the analysis. The overall VAS-F score was 3 (IQR 1-6). Patients with IIMs had similar fatigue scores (5, IQR 3-7) to non-IIM SAIDs [5 (IQR 2-7)], but higher compared to HCs (2, IQR 1-5; P < 0.001), regardless of disease activity. In adjusted analysis, higher VAS-F scores were seen in females (reference female; coefficient -0.17; 95%CI -0.21 to -13; P < 0.001) and Caucasians (reference Caucasians; coefficient -0.22; 95%CI -0.30 to -0.14; P < 0.001 for Asians and coefficient -0.08; 95%CI -0.13 to 0.30; P = 0.003 for Hispanics) in our cohort. Our study found that patients with IIMs exhibit considerable fatigue, similar to other SAIDs and higher than healthy individuals. Women and Caucasians experience greater fatigue scores, allowing identification of stratified groups for optimized multidisciplinary care and improve outcomes such as quality of life.
No takes yet. Share an insight, caveat, or question.
Grignaschi et al. (2023) conducted a cross-sectional in Idiopathic inflammatory myopathies (n=6,988). Idiopathic inflammatory myopathies vs. Healthy controls and non-IIM systemic autoimmune diseases was evaluated on Fatigue visual analog scale (VAS-F) score (0-10 cm) (p=<0.001). Patients with idiopathic inflammatory myopathies exhibited significantly higher fatigue scores compared to healthy controls (median VAS-F 5 vs 2, p<0.001), with levels comparable to other systemic autoimmune diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: